BDNF levels and change with treatment in patients with bipolar disorder manik episode;Bipolar bozukluk manik epizotta BDNF düzeyleri ve tedavi ile deǧişimi

Klinik Psikofarmakoloji Bulteni

Volumn 19, Issue SUPPL. 1, 2009, Pages

  Göka, Erol ^a,c   Göka, Sema ^b   Aydemir, Çiǧdem ^a   Aksaray, Sabahat ^c   Yalçin, Esra Süer ^a   Kisa, Cebrail ^a  

^a I Psikiyatri Kliniǧi ^*  (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bipolar disorder; Brain derived neurotrophic factor (BDNF); Mania

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; BIPOLAR MANIA; BLOOD SAMPLING; CENTRIFUGATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; LITERATURE; MALE; TREATMENT DURATION; VENOUS BLOOD; YOUNG MANIA RATING SCALE;

EID: 67650727207     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Stephen M. Stahl. Temel Psikofarmakoloji, Çeviri Ed: B. Taneli, Y. Yaneli. İstanbul, Yelkovan Yayincilik, 2000; 5: 135-198.
2. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 235: 1154-1162. (Pubitemid 17124912)
3. Carvey PM. Drug Action in the Central Nervous System. Oxford University Pres, New York, 1998.
4. Sah DWY, Ossipov MH, Porreca F. Neuropathic factors as novel therapeutics for neuropathic pain. Nature Reviews 2003; 2: 460-472. (Pubitemid 37361727)
5. Aydemir C, Yalcin ES, Aksaray S, Kisa C, yildirim SG, Uzbay T, Goka E. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1256-1260.
6. Gönül AS, Akdeniz F, Taneli F. Donat O, Eker C, Vahip S. Effect of treatment on brain-derived neurotrophic factor levels in depressed patients.Clin Neurosci 2005;112:110-116
7. Aydemir Ö, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neutrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 : 261-265 (Pubitemid 40202912)
8. T Fukumoto, S Morinobu, Y Okamoto, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurothopic factor in the rat brain. Psychopharmacology 2001; 158: 100-106. (Pubitemid 32938319)
9. R Hashimato, N Takei, K Shimazu, L Christ, B Lu, DM, Chuang. Lithium induces brain-derived neurotrophic factor and activities Trk B in rodent neurons: an essential step for neuro-protection against glutamate excitotoxicity. Neuropharmacology 2002; 43: 1173-1179 (Pubitemid 36009371)
10. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-metyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U.S.A. 1998; 95: 2642-2647 (Pubitemid 28145996)
11. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell dencity and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-553 (Pubitemid 32523734)
12. Wang JF, Asghari V, Rockel C, Young LT. Cyclic AMP responsiviness element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience 1999; 91: 771-776 (Pubitemid 29193284)
13. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibilility to bipolar disorders: evidence from a family-based association study. Am J Hum Genet 2002; 71: 651-655. (Pubitemid 34970137)
14. Sklar P, Gabriel SB, Mclnnis MG,Bennett P, Lim YM, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DcPaula JR, Lander ES. Family-based association study of 76 candilate genes in bipolar disorders: BDNF is a potential risk locus. Mol Psychiatry 2002; 7: 579-593. (Pubitemid 34888421)
15. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalvez CA, Santin A, Kapczinki F. Serum brain-derived neurotropic factor is decreased in bipolar disorder during depresive and manic episodes. Neurosci Lett 2006;8:215-219 (Pubitemid 43673698)
16. Monteleone P, Seritella C, Martiadis V, Maj M. Decreased levels of brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10: 95-100.
17. Brain- derived neurotrophic factor and neuroplasticity in bipolar disorder. Kapczinki F, Frey BN, Kaver-Sant'Anna M, Grassi-Oliveira R. Expert rev Neurother 2008, 8: 1101-1113 (Pubitemid 351962077)
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version American Psychiatric Pres. 1997; Washington. ( çev. Çorapçioǧlu A. 1999, Hekimler Yayin Birliǧi. Ankara) .
19. Young RC, Biggs T, Ziegler Meyer DA. A rating scale for mania, reliability, validy and sensitivity. Br J Psychiatry 1978; 133: 428-435. (Pubitemid 9006756)
20. F Karadaǧ, ET Oral, FA Yalçin, E Erten. Young Mani Derecelendirme Ölçeǧinin Türkiye'de Geçerlilik ve Güvenilirliǧi. Türk Psikiyatri Dergisi 2002;13: 107-114.
21. Kapczinki F, Frey BN, Andreazza AC, Kaver-Sant'Anna M, Cunha AB, Post RM. Increased oxidative stres as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008, 30; 243-245
22. Tseng M, aldo M, Xu L, Sun X, Wang JF, Graf P, Turecki G, Rouleou G, Young LT. BDNF protein levels are decreased in transformed lymphoblasts from lithium- responsive patients with bipolar disorder. J. Psychiatry Neurosci 2008, 33: 449-453
23. Pirildar S, Gonul AS, Taneli F, Akdeniz F. Low serum levels of brain derived neurotrophic factor in patients with schizophrenia do not elevate antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 709-713. (Pubitemid 38987396)
24. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okado S, Iyo M. Alterations of serum levels of Brain- Derived Neurotrophic Factor(BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-75. (Pubitemid 36776725)
25. Pan W, Banks WA, Fasold MB,Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood- brain barrier. Neuropharmacology 1998; 37: 1553-1561 (Pubitemid 28550429)
26. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Berschy G. Low brain-derived neurotrophic factor(BDNF) level is serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57 : 1068-1072 (Pubitemid 40613035)
27. Radka SF, Holst PA, Fritsche M, Atlar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensivite and specific immunoassay. Brain Res 1996; 709: 122-130 (Pubitemid 26063270)
28. Karege F, Schwald M, Cisse M. Postnatal developmental profilo of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-264 (Pubitemid 34876661)